Clinical trial of Durvalumab immunotherapy in GBM

Cure Brain Cancer Foundation is helping to fund this clinical trial, which will see Australian researchers joining forces with global counterparts to evaluate the effectiveness of an immunotherapy called durvalumab (MEDI4736) in patients with GBM.